• About Us
    • Our Purpose
    • Our Strategy
    • What we do
    • Our Impact
    • Our team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Support Calendar – What’s On
    • In-Person Support Events
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
      • Open Space
      • Group Counselling Programme
    • Recently diagnosed
    • Schools
    • Siblings
    • End of Life and Bereavement
  • AD Annual International Conference
    • Highlights from the Action Duchenne Conference 2025
    • Action Duchenne Annual International Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
  •  0 items - £0.00
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to secondary navigation
  • Skip to footer

Before Header

  • My account
  •  0 items - £0.00

Action Duchenne

Header Right

  • About Us
    • Our Purpose
    • Our Strategy
    • What we do
    • Our Impact
    • Our team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Support Calendar – What’s On
    • In-Person Support Events
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
      • Open Space
      • Group Counselling Programme
    • Recently diagnosed
    • Schools
    • Siblings
    • End of Life and Bereavement
  • AD Annual International Conference
    • Highlights from the Action Duchenne Conference 2025
    • Action Duchenne Annual International Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us

News

You are here: Home / News

Action Duchenne represent our community at bone protective therapy ENMC workshop

June 6, 2018 by abzali123

Bone Protective Therapy in Duchenne MD Date: 2018-06-03 Number: 236 City: Hoofddorp, The Netherlands Description: 236th ENMC …

Action Duchenne represent our community at bone protective therapy ENMC workshopRead More

Take part in ventilator study and earn £75

June 5, 2018 by abzali123

SuAzio are currently conducting a study and are looking for individuals who live with Duchenne, or their caregivers to be part of this study. …

Take part in ventilator study and earn £75Read More

CHMP Adopts Positive Opinion for the Expansion of the Translarna (ataluren) Label to Include Patients as Young as 2 Years of Age

June 4, 2018 by abzali123

- European Commission ratification anticipated in coming months - - Approval of the Translarna annual re-assessment also recommended by CHMP - PTC …

CHMP Adopts Positive Opinion for the Expansion of the Translarna (ataluren) Label to Include Patients as Young as 2 Years of AgeRead More

As Expected, Sarepta Receives Negative CHMP Opinion for EXONDYS (eteplirsen) to Treat Patients with Duchenne in Europe

June 1, 2018 by abzali123

Sarepta will seek re-examination of the opinion and request that a Scientific Advisory Group (SAG) be convened Sarepta have announced that the …

As Expected, Sarepta Receives Negative CHMP Opinion for EXONDYS (eteplirsen) to Treat Patients with Duchenne in EuropeRead More

Daiichi Sankyo announces Phase 1/2 clinical trial results

May 29, 2018 by abzali123

Daiichi Sankyo have announced the top-line results of the Phase 1/2 clinical trial in Japan of DS-5141), which Daiichi Sankyo is jointly …

Daiichi Sankyo announces Phase 1/2 clinical trial resultsRead More

Support for the Shippey family at their annual Golf Day

May 24, 2018 by abzali123

96 amazing golfers and a further 34 evening guests gathered to support the wonderful Shippey family at their second annual Cure4George charity golf …

Support for the Shippey family at their annual Golf DayRead More

Sarepta collaborate with Invitae to speed up diagnosis of Duchenne

May 23, 2018 by abzali123

Muscular Dystrophy News Today have reported that Sarepta Therapeutics and Invitae, a company specialising in genetic diagnostics, are …

Sarepta collaborate with Invitae to speed up diagnosis of DuchenneRead More

Thomas Blumire’s music to be performed at West Midlands concert

May 21, 2018 by abzali123

Music of Life Foundation is a small charity that uses  music-making to advance education and improve the health and wellbeing of disabled …

Thomas Blumire’s music to be performed at West Midlands concertRead More

FDA Grants Orphan Drug Designation to Sarconeos

May 17, 2018 by abzali123

BIOPHYTIS have announced that the US Food and Drug administration (FDA) has granted orphan drug designation to its drug candidate, Sarconeos. In …

FDA Grants Orphan Drug Designation to SarconeosRead More

Solid announces upcoming pre-clinical data presentations

May 17, 2018 by abzali123

Solid have announced that new pre-clinical data from its Duchenne programs, including its lead gene transfer candidate, SGT-001, will be …

Solid announces upcoming pre-clinical data presentationsRead More

Teachers brave the Zipwire!

May 17, 2018 by abzali123

This weekend saw an amazing group of teachers and supporters from Bruntcliffe Academy take on the world's fastest, and Europe's longest …

Teachers brave the Zipwire!Read More

NICE update on Eteplirsen

May 11, 2018 by abzali123

Following last week’s announcement that Sarepta’s exon skipping drug, Eteplirsen, had received a negative trend vote from the …

NICE update on EteplirsenRead More

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • Page 41
  • Interim pages omitted …
  • Page 48
  • Go to Next Page »

Footer

Action Duchenne
5th Floor, Mariner House
62 Prince Street
Bristol
BS1 4QD

07535 498 506
info@actionduchenne.org 

 

 

 

 

 

 

 

 

Subscribe to our mailing list

Do you consent to receiving regular email updates? *
Email Format
  • Accessibility
  • Privacy Policy
  • Terms & Conditions

© Action Duchenne - Registered Charity No 1101971 - Scottish Charity No SC043852

Like most websites we use cookies to deliver a personalised service. To use the website as intended please accept cookies.
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT